Premal H. Patel

3.7k total citations · 1 hit paper
50 papers, 2.5k citations indexed

About

Premal H. Patel is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Premal H. Patel has authored 50 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 26 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Premal H. Patel's work include PI3K/AKT/mTOR signaling in cancer (15 papers), Lung Cancer Treatments and Mutations (9 papers) and Liver physiology and pathology (8 papers). Premal H. Patel is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (15 papers), Lung Cancer Treatments and Mutations (9 papers) and Liver physiology and pathology (8 papers). Premal H. Patel collaborates with scholars based in United States, Spain and France. Premal H. Patel's co-authors include Lawrence A. Loeb, Robert J. Motzer, R.S.K. Chaganti, B D Preston, Amy Peterson, Elinor T. Adman, Akeo Shinkai, Rajendrakumar S.V. Chadalavada, Robert L. Yauch and Rafael E. Curiel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Premal H. Patel

49 papers receiving 2.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

2013 370 citations David R. Spigel, Thomas J. Ervin et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Premal H. Patel United States	22	1.5k	996	666	489	346	50	2.5k
Hüseyin Sirma Germany	31	1.9k 1.2×	655 0.7×	746 1.1×	639 1.3×	358 1.0×	52	3.1k
Paul B. Robbins United States	30	1.0k 0.7×	758 0.8×	1.7k 2.6×	385 0.8×	138 0.4×	79	3.1k
William L. Ince United States	15	691 0.5×	1.1k 1.1×	1.1k 1.6×	328 0.7×	110 0.3×	19	2.3k
Zenta Tsuchihashi United States	26	1.6k 1.0×	559 0.6×	1.0k 1.5×	144 0.3×	134 0.4×	47	4.4k
Pier Paolo Scaglioni United States	32	2.9k 1.9×	345 0.3×	1.1k 1.6×	760 1.6×	847 2.4×	61	4.5k
Shalini S. Yadav United States	21	840 0.6×	481 0.5×	940 1.4×	388 0.8×	86 0.2×	53	2.4k
Roland E. Knoblauch United States	22	738 0.5×	1.3k 1.3×	1.1k 1.7×	225 0.5×	63 0.2×	85	2.2k
Rikke Fredslund Andersen Denmark	31	975 0.6×	556 0.6×	964 1.4×	1.3k 2.6×	78 0.2×	115	2.8k
Sandra Franco Spain	28	585 0.4×	320 0.3×	930 1.4×	203 0.4×	532 1.5×	77	2.2k
Shannon R. Morris United States	23	980 0.7×	354 0.4×	872 1.3×	179 0.4×	138 0.4×	57	2.0k

Countries citing papers authored by Premal H. Patel

Since Specialization

Citations

This map shows the geographic impact of Premal H. Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Premal H. Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Premal H. Patel more than expected).

Fields of papers citing papers by Premal H. Patel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Premal H. Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Premal H. Patel. The network helps show where Premal H. Patel may publish in the future.

Co-authorship network of co-authors of Premal H. Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Premal H. Patel. A scholar is included among the top collaborators of Premal H. Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Premal H. Patel. Premal H. Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Premal H., et al.. (2024). In-silico APPROACH FOR VIRTUAL SCREENING AND MOLECULAR DOCKING OF FLAVONOIDS AS ERBB4 KINASE INHIBITORS IN THE TREATMENT OF CANCER. RASAYAN Journal of Chemistry. 17(2). 605–610.

Malhi, Vikram, Nageshwar Budha, Rucha Sane, et al.. (2021). Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Cancer Chemotherapy and Pharmacology. 88(6). 921–930. 4 indexed citations

Shapiro, Geoffrey I., Patricia LoRusso, Daniel C. Cho, et al.. (2020). A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. Investigational New Drugs. 39(1). 163–174. 23 indexed citations

Bono, Johann S. de, Ugo De Giorgi, Daniel Nava Rodrigues, et al.. (2018). Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clinical Cancer Research. 25(3). 928–936. 227 indexed citations

Greene, Stephanie, Angel E. Dago, Yipeng Wang, et al.. (2016). Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. PLoS ONE. 11(11). e0165089–e0165089. 37 indexed citations

Jia, Shidong, Sarah K. Baird, Amanda Anderson, et al.. (2016). Circulating tumor cell (CTC) detection, N-terminal androgen (AR) characterization, and PTEN loss in metastatic or advanced castration resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 34(2_suppl). 195–195. 1 indexed citations

Oliveira, Mafalda, Cristina Saura, Antonio González-Martı́n, et al.. (2015). FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 33(15_suppl). TPS1112–TPS1112. 1 indexed citations

Salgia, Ravi, Premal H. Patel, John Bothos, et al.. (2014). Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 20(6). 1666–1675. 56 indexed citations

Penuel, Elicia, Congfen Li, Luciana Burton, et al.. (2013). HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 12(6). 1122–1130. 20 indexed citations

10.

Dhillon, Gundeep, Vincent G. Valentine, Joseph E. Levitt, et al.. (2011). Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. Clinical Transplantation. 26(1). 105–110. 7 indexed citations

11.

Spigel, David R., Thomas J. Ervin, Rodryg Ramlau, et al.. (2011). Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.. Journal of Clinical Oncology. 29(15_suppl). 7505–7505. 149 indexed citations

12.

Tabernero, Josep, Cristina Saura, Susana Roselló, et al.. (2011). First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068.. Journal of Clinical Oncology. 29(15_suppl). 3022–3022. 10 indexed citations

13.

Moss, Rebecca A., John Bothos, Ellen Filvaroff, et al.. (2010). Phase Ib dose-escalation study of MetMAb, a monovalent antagonist antibody to the receptor MET, in combination with bevacizumab in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 28(15_suppl). e13050–e13050. 8 indexed citations

14.

Salgia, Ravi, Amy Peterson, John Bothos, et al.. (2010). Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors. Cancer Research. 70(8_Supplement). 2774–2774. 1 indexed citations

15.

Patel, Premal H., G. Varuni Kondagunta, Lawrence H. Schwartz, et al.. (2007). Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Investigational New Drugs. 26(3). 273–276. 16 indexed citations

16.

Patel, Premal H., G. Varuni Kondagunta, Bruce G. Redman, et al.. (2007). Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 25(18_suppl). 5097–5097. 6 indexed citations

17.

Patel, Premal H. & Lawrence A. Loeb. (2001). Getting a grip on how DNA polymerases function.. Nature Structural Biology. 8(8). 656–659. 62 indexed citations

18.

Patel, Premal H., Motoshi Suzuki, Elinor T. Adman, Akeo Shinkai, & Lawrence A. Loeb. (2001). Prokaryotic DNA polymerase I: evolution, structure, and “base flipping” mechanism for nucleotide selection. Journal of Molecular Biology. 308(5). 823–837. 159 indexed citations

19.

Patel, Premal H. & Lawrence A. Loeb. (2000). Multiple Amino Acid Substitutions Allow DNA Polymerases to Synthesize RNA. Journal of Biological Chemistry. 275(51). 40266–40272. 95 indexed citations

20.

Patel, Premal H., Alfredo Jacobo‐Molina, Jianping Ding, et al.. (1995). Insights into DNA Polymerization Mechanisms from Structure and Function Analysis of HIV-1 Reverse Transcriptase. Biochemistry. 34(16). 5351–5363. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact